和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02142 和铂医药-B

未开盘 05-06 16:08:10

12.860

-0.210

-1.61%

最高13.140	最低12.490	成交量308.00万
今开13.070	昨收13.070	日振幅4.97%
总市值112.14亿	流通市值112.14亿	总股本8.72亿
成交额3,925万	换手率0.35%	流通股本8.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"和铂医药-B","latestPrice":12.86,"timestamp":1778054890003,"preClose":13.07,"halted":0,"volume":3080000,"delay":0,"changeRate":-0.016067329762815673,"floatShares":872000000,"shares":872000000,"eps":0.11,"marketStatus":"未开盘","change":-0.21,"latestTime":"05-06 16:08:10","open":13.07,"high":13.14,"low":12.49,"amount":39246980,"amplitude":0.049732,"askPrice":12.86,"askSize":4000,"bidPrice":12.85,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":0.817,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778117400000},"marketStatusCode":0,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":13.07,"openAndCloseTimeList":[[1778031000000,1778040000000],[1778043600000,1778054400000]],"volumeRatio":1.296421027664245,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142/wiki","defaultTab":"wiki","newsList":[{"id":"1102534764","title":"和铂医药-B回购80万股股份，总额约1,027.33万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102534764","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102534764?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:42","pubTimestamp":1778067751,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年5月6日发布公告，披露于香港联交所场内回购800,000股普通股，占当日公司已发行股本的0.0917%。本次回购的最高价为每股13.1港元，最低价为每股12.5港元，合计耗资约10,273,300港元，回购股份预期转为库藏股。公告显示，此次股份购回已依据公司于2025年6月11日通过的购回授权进行，授权可回购股份总数为82,834,612股，截至目前公司已于香港联交所或其他证券交易所合计回购9,200,000股，占该授权通过当日已发行股本约1.11%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B回购80万股股份，总额约1,027.33万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633180803","title":"和铂医药-B(02142)5月6日斥资1027.33万港元回购80万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2633180803","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633180803?lang=zh_cn&edition=full","pubTime":"2026-05-06 19:37","pubTimestamp":1778067460,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，于2026年5月6日，该公司斥资1027.33万港元回购80万股股份，每股回购价12.5-13.1港元。于2026年5月6日，该公司根据于2020年11月23日采纳及获公司股东批准的首次公开发售后股份奖励计划而发行1.1万股普通股以满足股份奖励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117721878","title":"和铂医药-B于5月5日回购30万股，涉资约388.23万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117721878","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117721878?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:12","pubTimestamp":1777979538,"startTime":"0","endTime":"0","summary":"根据和铂医药-B于2026年5月5日发布的公告，公司于同日回购股份30万股，占回购前公司已发行股本约0.0344%，回购价格介乎每股12.75港元至13.06港元，合计支出约388.23万港元。本次股份变动后，公司已发行股本增加至8.72124722亿股，库藏股数量升至2673.7万股，总股本为8.98861722亿股。公告另提及，相关回购完成后，新的股份发行及库藏股再出售或转让的暂止期至2026年6月4日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B于5月5日回购30万股，涉资约388.23万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154987893","title":"和铂医药-B 2026年5月4日回购50万股股份，总金额约649.94万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154987893","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154987893?lang=zh_cn&edition=full","pubTime":"2026-05-04 20:02","pubTimestamp":1777896145,"startTime":"0","endTime":"0","summary":"2026年5月4日，和铂医药控股有限公司发布翌日披露报表。公告显示，当日公司于香港联交所回购普通股50万股，占买入前已发行股份总数约0.0573%，每股回购价介乎12.81港元至13.28港元，合计涉资约649.94万港元，上述股份被列作库藏股持有。公司于2025年6月11日通过购回授权，授权总数为82,834,612股，截至目前已累计回购8,100,000股，占授权时已发行股份约0.98%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B 2026年5月4日回购50万股股份，总金额约649.94万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632958637","title":"和铂医药-B(02142)5月4日斥资649.94万港元回购50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2632958637","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632958637?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:58","pubTimestamp":1777895936,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，于2026年5月4日斥资649.94万港元回购50万股;根据于2020年11月23日采纳及获本公司股东批准的首次公开发售后股份奖励计划而发行4.1万股普通股以满足股份奖励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128942985","title":"和铂医药-B2025年扭亏为盈：收入攀升至1.58亿美元，全球合作与创新研发同步加速","url":"https://stock-news.laohu8.com/highlight/detail?id=1128942985","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128942985?lang=zh_cn&edition=full","pubTime":"2026-04-28 21:48","pubTimestamp":1777384119,"startTime":"0","endTime":"0","summary":"和铂医药-B在2025年度实现营收显著增长，全年收入从2024年的3,810万美元增至1.58亿美元，同比提升314.58%。期间，公司净利润录得9,222.10万美元，较2024年同期274.20万美元大幅增长3,264.10%，从此前的亏损状态顺利扭亏为盈。基本每股盈利为0.12美元，摊薄每股盈利为0.11美元。公司认为，随着免疫治疗领域的发展机遇增加，企业将在全球范围内继续拓展研发合作，不断完善其技术及产品布局，为多种重大疾病的治疗提供更多创新解决方案。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B2025年扭亏为盈：收入攀升至1.58亿美元，全球合作与创新研发同步加速","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1170622760","title":"和铂医药-B授权董事股份购回，规模达已发行股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170622760","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170622760?lang=zh_cn&edition=full","pubTime":"2026-04-28 21:47","pubTimestamp":1777384044,"startTime":"0","endTime":"0","summary":"和铂医药-B在港交所公告称，公司拟在即将召开的股东周年大会上寻求授予董事一般及无条件的股份购回授权，规模最高可达当日公司已发行股份总数的10%。公司目前已发行股本为约8.99亿股，其中包含2593.70万股库存股份，若相关决议获批，则公司最多可购回约8725.84万股。董事会认为，这符合公司及股东的整体最佳利益。董事会同时建议，根据回购授权实际行使的股份数量，发行授权的可用规模也将相应扩大。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和铂医药-B授权董事股份购回，规模达已发行股本10%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151470916","title":"和铂医药-B更新3月股份变动月报表，新增发行259,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1151470916","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151470916?lang=zh_cn&edition=full","pubTime":"2026-04-10 06:21","pubTimestamp":1775773296,"startTime":"0","endTime":"0","summary":"根据和铂医药控股有限公司于2026年4月9日发布的截至2026年3月31日的月报表显示，公司法定股本维持在20,000,000,000股，面值为每股0.000025美元，法定股本总额500,000美元，较上月无变化。与上月相比，普通股数量增加259,000股，主要源于“首次公开发售后股份奖励计划”授予的股份。公司披露，报告期末共有39,033,100份股份期权未行使，并无新增授出、行使或失效情况。该报告由公司执行董事王劲松签署，并确认所有股份变动已遵循相关上市规则及法定程序。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161385586","title":"和铂医药-B更新3月股份变动月报表，股本略有增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1161385586","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161385586?lang=zh_cn&edition=full","pubTime":"2026-04-09 22:55","pubTimestamp":1775746552,"startTime":"0","endTime":"0","summary":"和铂医药控股有限公司于2026年4月9日披露截至2026年3月31日的股份变动月报表，报告期内公司授权股本维持不变，面值为每股USD 0.000025，共计20,000,000,000股，注册股本总额为USD 500,000。库存股份保持在25,937,000股不变，因此公司本月末已发行股份总数为895,787,522股。本月增发主要源于首次公开发售后购股权计划的行使，行使数量为259,000股。公司确认，报告期内的所有股份发行和购回活动均遵守香港联交所《上市规则》及法律法规的相关要求。本次月报表由执行董事王劲松签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624739475","title":"【券商聚焦】华安证券维持和铂医药-B(02142)“买入”评级 指公司迈入高增长可持续盈利闭环","url":"https://stock-news.laohu8.com/highlight/detail?id=2624739475","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624739475?lang=zh_cn&edition=full","pubTime":"2026-04-02 14:35","pubTimestamp":1775111716,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华安证券发布研报指，和铂医药-B 2025年业绩创历史新高，迈入高增长可持续盈利闭环。2025年全年，和铂医药实现营收1.58亿美元，同比增长314.63%；归母净利润0.91亿美元，同比增长3187.72%。研发费用总额为0.40亿美元，同比增长89.38%，持续为后续发展提供驱动力。其中与阿斯利康的联合实验室已于2026年3月正式启用。2026年，公司计划继续达成规模化产品授权，并推进移除港股“B”标记、冲刺港股通。维持对和铂医药-B“买入”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/ZjI2Mjk2NDJlMTg0ZTY2MjVhYzY3MmYxYmE2MzM4MDk2MjYyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZjI2Mjk2NDJlMTg0ZTY2MjVhYzY3MmYxYmE2MzM4MDk2MjYyNA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978156","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","600909"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164403973","title":"异动解读 | 业绩强劲、合作突破，和铂医药-B盘中大涨9.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164403973","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164403973?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:24","pubTimestamp":1775021057,"startTime":"0","endTime":"0","summary":"和铂医药-B(02142)今日盘中股价大幅上涨9.54%，表现十分亮眼。消息面上，公司近期发布的2025年业绩报告显示，全年总收入达1.58亿美元，同比增长超过4倍，净利润大幅增长至9222万美元，现金储备充裕。此外，公司在全球合作方面取得突破性进展，与阿斯利康、百时美施贵宝等大型跨国药企达成了多项战略合作，潜在交易总额可观，为未来收入提供了强劲动力。管理层在业绩说明会上透露，公司的AI制药平台已深度赋能研发，显著缩短项目周期，并有项目接近临床试验申请阶段。同时，公司给出了2026年营收增长40%至50%的积极指引，并计划加大研发投入，市场对其未来增长潜力和盈利能力信心大增。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624561377","title":"直击业绩会｜和铂医药2025年全球合作与产品授权驱动收入增长超4倍，管理层：与大型跨国药企合作可反哺早期研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2624561377","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624561377?lang=zh_cn&edition=full","pubTime":"2026-04-01 12:35","pubTimestamp":1775018103,"startTime":"0","endTime":"0","summary":"3月30日晚间，和铂医药发布2025年业绩报告，全年实现总收入1.58亿美元，上年同期为3810万美元，收入主要包括分子许可费、研究服务及技术许可费；净利润9222万美元，去年同期为274万美元；公司现金及现金等价物达4.03亿美元，上年同期为1.67亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604013691707928.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013691707928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK1583","02142","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623535508","title":"和铂医药-B(02142)授出10.3万股股份奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2623535508","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623535508?lang=zh_cn&edition=full","pubTime":"2026-03-31 23:43","pubTimestamp":1774971818,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，于2026年3月31日，根据股东于2020年11月23日采纳的股份奖励计划，公司向一名合资格参与者授出10.3万股股份奖励，但须待该承授人接纳后生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423518.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02142","BK1583","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623304962","title":"33倍净利增长，和铂医药如何将BD变成常态化“印钞机”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2623304962","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623304962?lang=zh_cn&edition=full","pubTime":"2026-03-31 16:28","pubTimestamp":1774945680,"startTime":"0","endTime":"0","summary":"3月30日，和铂医药（02142.HK）公布了2025年度业绩。财报显示，公司全年总收入约11.1亿元人民币，同比增长314.6%；全年净利润约6.48亿元，同比增长33倍；经调整净利润约7.09亿元，同比增长11倍。截至2025年底，现金及现金等价物增至28.33亿元，较上年末增长141.6%。从账面数据看，这是一份颇为亮眼的成绩单。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603313690416970.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603313690416970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623723953","title":"盈利33倍，和铂医药凭什么成为“确定性资产”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2623723953","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623723953?lang=zh_cn&edition=full","pubTime":"2026-03-31 12:09","pubTimestamp":1774930173,"startTime":"0","endTime":"0","summary":"和铂医药不再是一家赌临床数据的传统Biotech，而是一个掌握全球稀缺底层技术、具备常态化造血能力、与MNC深度绑定的“技术基建商”。","market":"hk","thumbnail":"https://img2.gelonghui.com/b17e2-c747d72b-9b53-4b59-8164-252fd1f5ff31.jpg?guru_height=720&guru_width=1280&guru_size=154189","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/b17e2-c747d72b-9b53-4b59-8164-252fd1f5ff31.jpg?guru_height=720&guru_width=1280&guru_size=154189"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4246709","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","02142","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174265763","title":"异动解读 | 和铂医药-B盘中大涨5.28%，2025年业绩亮眼净利润大增32倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1174265763","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174265763?lang=zh_cn&edition=full","pubTime":"2026-03-31 09:54","pubTimestamp":1774922079,"startTime":"0","endTime":"0","summary":"和铂医药-B今日盘中股价大幅上涨5.28%，引起了市场的广泛关注。消息面上，公司于前一交易日盘后公布了2025年度业绩报告，数据显示其业绩表现极为强劲。报告期内，公司总收入约1.58亿美元，同比增长超过314%；年内溢利达到9222.1万美元，同比大幅增长约32.63倍。公司现金及现金等价物也显著增长，显示出强大的财务实力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623434187","title":"和铂医药-B(02142)公布2025年业绩 税后溢利9222.1万美元 同比增长约32.63倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2623434187","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623434187?lang=zh_cn&edition=full","pubTime":"2026-03-30 22:49","pubTimestamp":1774882160,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)公布2025年业绩，收入约1.58亿美元，同比增长314.63%;年内溢利9222.1万美元，同比增长约32.63倍;基本每股盈利0.12美元。于2025年，公司全面迈入3.0战略阶段，由三大增长引擎协同驱动：将诺纳生物打造为AI驱动的全球抗体药物发现“新基建”;与跨国制药公司建立长期、平台化的战略合作伙伴关系，以加速全球扩张;通过Harbour Therapeutics实现在自免、肿瘤等领域的中后期资产全球价值的最大化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1422250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"和铂医药-B(02142)公布2025年业绩 税后溢利9222.1万美元 同比增长约32.63倍","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","02142","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193648759","title":"和铂医药-B公布2025财年业绩：持续全球合作夯实长期增长根基","url":"https://stock-news.laohu8.com/highlight/detail?id=1193648759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193648759?lang=zh_cn&edition=full","pubTime":"2026-03-30 21:55","pubTimestamp":1774878918,"startTime":"0","endTime":"0","summary":"和铂医药-B发布2025财年完整财务报告，显示公司通过持续深化的全球战略合作，为长期可持续发展奠定了坚实基础。全球多中心临床研究项目稳步推进，跨境技术平台协同效应显著增强，共同推动创新管线价值加速释放。公司管理层表示，将继续依托自主知识产权的抗体技术平台，构建开放共赢的全球创新生态。亚洲及欧美市场临床数据持续产出，为后续商业化提供强有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1574","02142","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621059310","title":"港股异动 | TSLP抗体疗法I期临床研究结果发表 科伦博泰生物-B(06990)涨超7% 和铂医药-B(02142)涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621059310","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621059310?lang=zh_cn&edition=full","pubTime":"2026-03-24 15:02","pubTimestamp":1774335720,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B、和铂医药-B午后涨幅扩大。截至发稿，科伦博泰生物涨7.34%，报426.8港元；和铂医药涨4.65%，报11.7港元。消息面上，3月23日，和铂医药宣布，HBM9378首次人体1期临床试验结果已在线发表于同行评议期刊Drug Design, Development and Therapy。公开资料显示，HBM9378由和铂医药与科伦博泰联合开发，双方共同享有其全球权益。2025年1月，和铂医药及科伦博泰与Windward Bio签订战略合作，授予后者在全球范围内对该抗体进行研究、开发、生产和商业化的独家权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","02142","VXUS","BK1574","LU0196878994.USD","06990","BK4588","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174660573","title":"和铂医药任命谢博士为免疫学首席科学官兼全球外部创新负责人","url":"https://stock-news.laohu8.com/highlight/detail?id=1174660573","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174660573?lang=zh_cn&edition=full","pubTime":"2026-03-19 14:43","pubTimestamp":1773902595,"startTime":"0","endTime":"0","summary":"和铂医药-B（股票代码：02142）宣布一项重要人事任命，谢博士（Dr. Jenny Xie）正式加入公司，担任免疫学首席科学官兼全球外部创新负责人。这一任命将进一步加强公司在免疫学领域的科研实力与全球创新合作网络。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02142","BK1583"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0206},{"period":"1month","weight":-0.1113},{"period":"3month","weight":0.1565},{"period":"6month","weight":0.0231},{"period":"1year","weight":0.4833},{"period":"ytd","weight":0.0576}],"compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0437},{"period":"3month","weight":-0.025},{"period":"6month","weight":-0.0011},{"period":"1year","weight":0.1567},{"period":"ytd","weight":0.0228}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和铂医药控股有限公司是一家主要从事肿瘤免疫学及免疫性疾病领域的创新疗法开发业务的投资控股公司。该公司的产品主要包括巴托利单抗（HBM9161）、HBM9378、HBM7020、TCE Program、普鲁苏拜单抗（HBM4003）以及HBM7022等。该公司产品主要用于治疗全身型重症肌无力（gMG）、慢性阻塞性肺病（COPD）、哮喘、自身免疫疾病、黑色素瘤、结直肠癌以及实体瘤等。该公司通过专有抗体技术平台“Harbour Mice”、“HBICE”、“HBICA”及单克隆B细胞筛选平台提供下一代抗体以及生物解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083377},{"month":2,"riseRate":0.333333,"avgChangeRate":0.000026},{"month":3,"riseRate":0.5,"avgChangeRate":0.051559},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009952},{"month":5,"riseRate":0.5,"avgChangeRate":0.03179},{"month":6,"riseRate":0.2,"avgChangeRate":-0.066065},{"month":7,"riseRate":0.4,"avgChangeRate":0.030357},{"month":8,"riseRate":0.2,"avgChangeRate":0.005624},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065735},{"month":10,"riseRate":0,"avgChangeRate":-0.180686},{"month":11,"riseRate":0.8,"avgChangeRate":0.25789},{"month":12,"riseRate":0.6,"avgChangeRate":0.266929}],"exchange":"SEHK","name":"和铂医药-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和铂医药-B,02142,和铂医药-B股票,和铂医药-B股票老虎,和铂医药-B股票老虎国际,和铂医药-B行情,和铂医药-B股票行情,和铂医药-B股价,和铂医药-B股市,和铂医药-B股票价格,和铂医药-B股票交易,和铂医药-B股票购买,和铂医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和铂医药-B(02142)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和铂医药-B(02142)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}